id,filing_uuid,filing_type,registrant_name,registrant_id,client_name,filing_year,filing_period,issue_code,specific_issues,government_entities,income_amount,expense_amount,is_no_activity,is_termination,received_date
2286540,d7770ffc-e2ff-418d-9434-8d570c4c7f56,Q1,"JOHNSON & JOHNSON SERVICES, INC.",20686,JOHNSON & JOHNSON SERVICES INC,2019,first_quarter,HCR,"- H.R. 863 - DXM Abuse Prevention Act of 2019, regarding all provisions
- S. 726 - Personal Care Products Safety Act, regarding all provisions
- H.R. 269 - Pandemic and All-Hazards Preparedness & Advancing Innovation Act of 2019, regarding all provisions
- Issues related to the reputation of over-the-counter drugs
- Issues related to cosmetic regulatory reform
- Issues related to cosmetic animal testing
- Issues related to biosimilars
- Issues related to maternal mortality
- Issues related to contact lens safety
- Issues related to the medical device tax repeal
- Issues related to medical product communications
- Issues related to medical product review
- Issues related to talc safety
- Issues related to drug pricing reform
- Issues related to diversity in clinical trials
- Issues related to health care pricing transparency
- Issues related to peripheral artery disease","HOUSE OF REPRESENTATIVES,SENATE,White House Office",,1440000,0,0,2019-04-22T14:26:16.577000-04:00